All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

EHA 2024 abstracts: What’s hot in ALL?

Bookmark this article

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2024 Hybrid Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

Frontline and emerging therapies for ALL


Blinatumomab for first line treatment in intermediate and high risk Down Syndrome B-cell acute lymphoblastic leukaemia: Initial findings from the ALLTOGETHER1 DS TRIAL


Blinatumomab as consolidation in a paediatric protocol leads to high rates of end-consolidation MRD negativity and excellent outcomes in AYA ALL – Final results of the ALLG ALL09 "SUBLIME" STUDY


Blinatumomab added to prephase and consolidation therapy in adult B-ALL: A comparison of the consecutive HOVON-100 AND H-146 studies


Ponatinib versus imatinib in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in the phase 3 PHALLCON trial: In depth responder analysis


Augmented use of L-asparaginase markedly improves the treatment result of AYA ALL patients: Result of prospective MRD 2014 study conducted by Fukuoka Blood And Marrow Transplantation Group (FBMTG)


Ponatinib, chemotherapy and transplantation for newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Final results of the phase 2 PONALFIL trial


Busulfan plus cyclophosphamide vs. Total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia 


Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL): Post hoc analysis of adverse events of interest from AALL1931


Blinatumomab induction therapy following reduced-dose chemotherapy in newly diagnosed adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: Multicentre, single arm, phase 2 study


A full pediatric regimen for adult patients with Philadelphia negative acute lymphoblastic leukemia achieves excellent outcomes with acceptable toxicity


Blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL): Safety run-in follow-up for the phase 3 GOLDEN GATE study.


Combination of third generation TKI olverembatinib and chemotherapy or blinatumomab for new diagnosed adult Ph+ ALL patients


Improving outcome in elderly Philadelphia negative acute lymphoblastic leukemia: Feasibility and efficacy of an intensive PEG-asparaginase-based regimen

Treatments for relapsed/refractory ALL

Biomarkers, prognosis, and biology 

Real-world outcomes

EHA24 Top Abstracts

To download this document, click below.

Download here

More about...


Subscribe to get the best content related to ALL delivered to your inbox